-SK Bioscience is taking a roughly 7% stake in Novavax in lieu of some payment owed to the South Korean biotech company, giving the cash-strapped COVID-19 vaccine maker some breathing room..
Pfizer s plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street s expectations and will spur its revenue for years despite weaker than anticipated demand
With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu
By Michael Erman NEW YORK (Reuters) - With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting f.